Propel: Discovery – Preclinical Platform
What is propel: Discovery?
We aim to serve partners at every stage of development, including the preclinical market. We understand how challenging it is out there. Sometimes you just need a small amount of material for your proof-of-concept to raise the funds you need to get to the clinic. That’s where Genezen can help.
It is imperative to our mission and strategic goals to partner with early-stage and parent-founded organizations to help tackle the most challenging steps in the development and discovery process. Connect with us for your preclinical program needs, and we’ll get you started with the right vector when you need it most.
It’s never “too early” to start working with Genezen. Our support throughout the initial stages of your gene therapy development facilitates a seamless transition to clinical-grade manufacturing. These services encompass the production of research/preclinical-grade adeno-associated viral vectors, lentiviral vectors and retroviral vectors that meet your research standards and timelines.
- Rapid production of research-grade material using your therapeutic or reporter gene of interest
- Streamlined turnaround times enabled by
standardized processes, materials, and analytical methods - Ideal for construct screening to inform
candidate selection and early-stage decision making - Optional endotoxin testing available to support
preclinical animal studies - Designed with your clinical path in mind: we use scalable cell lines and processes that translate to GMP manufacturing, enabling a seamless transition to process development and clinical readiness—leveraging data from research-grade runs when the gene of interest remains unchanged
- Transparent, all-inclusive pricing with no hidden fees—what you see is what you get
